| pubmed-article:21558987 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0006142 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0043210 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0010583 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0144576 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0746319 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C1516119 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0031928 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
| pubmed-article:21558987 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:21558987 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:21558987 | pubmed:dateCreated | 2011-5-11 | lld:pubmed |
| pubmed-article:21558987 | pubmed:databankReference | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:abstractText | To examine the safety of sorafenib combined with standard adjuvant treatment in patients with node-positive or otherwise high-risk breast cancer. | lld:pubmed |
| pubmed-article:21558987 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21558987 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21558987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21558987 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21558987 | pubmed:month | Apr | lld:pubmed |
| pubmed-article:21558987 | pubmed:issn | 1543-0790 | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:HainsworthJoh... | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:GrecoF... | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:BurrisHoward... | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:SpigelDavid... | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:YardleyDenise... | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:KommorMichael... | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:VazquezElizab... | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:PeacockNancyN | lld:pubmed |
| pubmed-article:21558987 | pubmed:author | pubmed-author:MolthropDavid... | lld:pubmed |
| pubmed-article:21558987 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:21558987 | pubmed:volume | 9 | lld:pubmed |
| pubmed-article:21558987 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21558987 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21558987 | pubmed:pagination | 280-6 | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:meshHeading | pubmed-meshheading:21558987... | lld:pubmed |
| pubmed-article:21558987 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21558987 | pubmed:articleTitle | A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer. | lld:pubmed |
| pubmed-article:21558987 | pubmed:affiliation | Sarah Cannon Research Institute, Nashville, TN 37203, USA. dspigel@tnonc.com | lld:pubmed |
| pubmed-article:21558987 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21558987 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:21558987 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:21558987 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
